SCHEMBL4495141

SCHEMBL4495141

COc1ccccc1C(=O)Nc1n[nH]c2cc(Br)ccc12

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.60
HDAC6 Q9UBN7 6/20 0.58
MAPT P10636 2/20 0.56
GSK3B P49841 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
GPR35 Q9HC97 1/20 0.53
FGFR4 P22455 4/20 0.53
CDC7 O00311 1/20 0.51
MAP4K4 O95819 1/20 0.51
PIM1 P11309 1/20 0.51
CDK2 P24941 1/20 0.51
HIPK2 Q9H2X6 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491757 0.85 DYRK1A (0.64) DYRK1AHDAC6GSK3BNPC1RAB9A
SCHEMBL4475421 0.83 FGFR4 (0.68) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4483693 0.83 HDAC6 (0.59) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4494633 0.82 FGFR4 (0.60) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4491476 0.82 FGFR4 (0.60) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4490036 0.82 HDAC6 (0.66) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4490455 0.81 FGFR4 (0.62) HDAC6GSK3BFGFR4HDAC1HDAC2
SCHEMBL4487154 0.81 FGFR4 (0.58) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4486202 0.81 HDAC6 (0.64) HDAC6GSK3BFGFR4CDC7MAP4K4
SCHEMBL4483761 0.81 GSK3B (0.60) HDAC6GSK3BFGFR4CDC7MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 DYRK1A 298/4885HDAC6 675/4885MAPT 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.